165
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Innate lymphoid cells: A new paradigm in immunology

      1 , 2 , 3 , 4
      Science
      American Association for the Advancement of Science (AAAS)

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Cells acting at the intersection of immunity

          For years, scientists divided the immune system into two arms: innate and adaptive. The cell types involved in the two arms differ in specificity and in how quickly they respond to infections. More recently, immunologists discovered a family of immune cells termed “innate lymphoid cells,” which straddle these two arms. Eberl et al. review current understanding of innate lymphoid cells. Like innate immune cells, they respond to infection quickly and do not express antigen receptors; however, they secrete a similar suite of inflammatory mediators as T lymphocytes. Better understanding of the processes regulating these cells may allow for their therapeutic manipulation.

          Science , this issue [Related article:]10.1126/science.aaa6566

          Abstract

          A growing family of immune cells reacts promptly to signals from infected or injured tissues and tailors the immune response.

          Abstract

          BACKGROUND

          Innate lymphoid cells (ILCs) are a growing family of immune cells that mirror the phenotypes and functions of T cells. Natural killer (NK) cells can be considered the innate counterparts of cytotoxic CD8 + T cells, whereas ILC1s, ILC2s, and ILC3s may represent the innate counterparts of CD4 + T helper 1 (T H 1), T H 2, and T H 17 cells. However, in contrast to T cells, ILCs do not express antigen receptors or undergo clonal selection and expansion when stimulated. Instead, ILCs react promptly to signals from infected or injured tissues and produce an array of secreted proteins, termed cytokines, that direct the developing immune response into one that is adapted to the original insult. Thus, the power of ILCs may be controlled or unleashed to regulate or enhance immune responses in disease prevention and therapy.

          ADVANCES

          As with B cells and T cells, ILCs develop from the common lymphoid progenitor, but dedicated transcription factors supress the B and T cell fates and direct the generation of the different types of ILCs. ILC precursors may migrate from their primary site of production into infected and injured tissues, where they complete their maturation, similar to the differentiation of naïve T cells into T H effectors. Cytokines produced by local cells as well as stress ligands and bacterial and dietary compounds regulate the maturation and activation of ILCs into effectors that play a major role in early immune responses to pathogens and symbionts, helminths, and allergen. The cytokines they produce induce innate responses in stromal, epithelial, and myeloid cells and regulate the activity of dendritic cells (DCs), which play a central role in the cross-talk between ILCs and T cells. In particular, ILCs activate tissue-resident DCs to migrate to lymph nodes, where they elicit specific T cell responses, which in turn regulate ILCs. ILCs also directly regulate T cells through the presentation of peptide antigens on major histocompatibility complex II. However, ILCs are also involved in immunopathology, during which their production of cytokines exacerbates the inflammatory process.

          ILCs also play an intriguing role beyond immunity. In adipose tissues, they regulate thermogenesis and prevent local inflammation that may lead to metabolic syndrome, insulin resistance, and obesity-associated asthma. The functions of ILCs in host metabolism are a new area of research that will lead to insights into how the immune system is implicated in host functions not directly related to defense. Furthermore, ILCs are involved in repair responses upon infection and injury of epithelial cells, stromal cells, and stem cells.

          OUTLOOK

          A logical next step will be the identification of molecules that allow manipulation of ILCs and the orchestration of the optimal immune response after vaccination and immunotherapy—or in contrast, to block detrimental responses. The combination of a prompt activation of ILCs with both effector and regulatory functions, with the expansion of antigen-specific B and T cells, should lead to new and powerful avenues in clinical immunology.

          Abstract

          Innate lymphoid cells (ILCs) are a growing family of immune cells that mirror the phenotypes and functions of T cells. However, in contrast to T cells, ILCs do not express acquired antigen receptors or undergo clonal selection and expansion when stimulated. Instead, ILCs react promptly to signals from infected or injured tissues and produce an array of secreted proteins termed cytokines that direct the developing immune response into one that is adapted to the original insult. The complex cross-talk between microenvironment, ILCs, and adaptive immunity remains to be fully deciphered. Only by understanding these complex regulatory networks can the power of ILCs be controlled or unleashed in order to regulate or enhance immune responses in disease prevention and therapy.

          Related collections

          Most cited references132

          • Record: found
          • Abstract: found
          • Article: not found

          Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.

          Diabetes and obesity are characterized by a low-grade inflammation whose molecular origin is unknown. We previously determined, first, that metabolic endotoxemia controls the inflammatory tone, body weight gain, and diabetes, and second, that high-fat feeding modulates gut microbiota and the plasma concentration of lipopolysaccharide (LPS), i.e., metabolic endotoxemia. Therefore, it remained to demonstrate whether changes in gut microbiota control the occurrence of metabolic diseases. We changed gut microbiota by means of antibiotic treatment to demonstrate, first, that changes in gut microbiota could be responsible for the control of metabolic endotoxemia, the low-grade inflammation, obesity, and type 2 diabetes and, second, to provide some mechanisms responsible for such effect. We found that changes of gut microbiota induced by an antibiotic treatment reduced metabolic endotoxemia and the cecal content of LPS in both high-fat-fed and ob/ob mice. This effect was correlated with reduced glucose intolerance, body weight gain, fat mass development, lower inflammation, oxidative stress, and macrophage infiltration marker mRNA expression in visceral adipose tissue. Importantly, high-fat feeding strongly increased intestinal permeability and reduced the expression of genes coding for proteins of the tight junctions. Furthermore, the absence of CD14 in ob/ob CD14(-)(/)(-) mutant mice mimicked the metabolic and inflammatory effects of antibiotics. This new finding demonstrates that changes in gut microbiota controls metabolic endotoxemia, inflammation, and associated disorders by a mechanism that could increase intestinal permeability. It would thus be useful to develop strategies for changing gut microbiota to control, intestinal permeability, metabolic endotoxemia, and associated disorders.
            • Record: found
            • Abstract: found
            • Article: not found

            Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

            Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophilic inflammation. They were randomly assigned (in a 1:1:1:1 ratio) to receive one of three doses of intravenous mepolizumab (75 mg, 250 mg, or 750 mg) or matched placebo (100 mL 0·9% NaCl) with a central telephone-based system and computer-generated randomly permuted block schedule stratified by whether treatment with oral corticosteroids was required. Patients received 13 infusions at 4-week intervals. The primary outcome was the rate of clinically significant asthma exacerbations, which were defined as validated episodes of acute asthma requiring treatment with oral corticosteroids, admission, or a visit to an emergency department. Patients, clinicians, and data analysts were masked to treatment assignment. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01000506. 621 patients were randomised: 159 were assigned to placebo, 154 to 75 mg mepolizumab, 152 to 250 mg mepolizumab, and 156 to 750 mg mepolizumab. 776 exacerbations were deemed to be clinically significant. The rate of clinically significant exacerbations was 2·40 per patient per year in the placebo group, 1·24 in the 75 mg mepolizumab group (48% reduction, 95% CI 31-61%; p<0·0001), 1·46 in the 250 mg mepolizumab group (39% reduction, 19-54%; p=0·0005), and 1·15 in the 750 mg mepolizumab group (52% reduction, 36-64%; p<0·0001). Three patients died during the study, but the deaths were not deemed to be related to treatment. Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. GlaxoSmithKline. Copyright © 2012 Elsevier Ltd. All rights reserved.
              • Record: found
              • Abstract: found
              • Article: not found

              NK cell recognition.

              The integrated processing of signals transduced by activating and inhibitory cell surface receptors regulates NK cell effector functions. Here, I review the structure, function, and ligand specificity of the receptors responsible for NK cell recognition.

                Author and article information

                Journal
                Science
                Science
                American Association for the Advancement of Science (AAAS)
                0036-8075
                1095-9203
                May 22 2015
                May 22 2015
                : 348
                : 6237
                Affiliations
                [1 ]Institut Pasteur, Microenvironment and Immunity Unit, 75724 Paris, France.
                [2 ]Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
                [3 ]Institut Pasteur, Innate Immunity Unit, INSERM U668, 75724 Paris, France.
                [4 ]Medical Research Council (MRC) Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.
                Article
                10.1126/science.aaa6566
                5658207
                25999512
                cb5be5ed-487e-4688-8132-a7dafe49d9cb
                © 2015

                http://www.sciencemag.org/about/science-licenses-journal-article-reuse

                History

                Comments

                Comment on this article

                Related Documents Log